Crossmark Global Holdings, Inc. Abb Vie Inc. Transaction History

Crossmark Global Holdings, Inc.

$5.22 Billion
Q1 2024

A detailed history of Crossmark Global Holdings, Inc. transactions in Abb Vie Inc. stock. As of the latest transaction made, Crossmark Global Holdings, Inc. holds 83,981 shares of ABBV stock, worth $13.8 Million. This represents 0.29% of its overall portfolio holdings.

Number of Shares

83,981

Previous 95,142 11.73%

Holding current value

$13.8 Million

Previous $14.7 Million 3.72%

% of portfolio

0.29%

Previous 0.31%

28 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 13, 2024	SELL	$159.82 - $182.1 $1.78 Million - $2.03 Million	-11,161 Reduced 11.73%	83,981 $15.3 Million
Q4 2023 Feb 13, 2024	BUY	$137.6 - $154.97 $239,148 - $269,337	1,738 Added 1.86%	95,142 $14.7 Million
Q3 2023 Nov 08, 2023	BUY	$133.59 - $154.65 $78,550 - $90,934	588 Added 0.63%	93,404 $13.9 Million
Q2 2023 Jul 31, 2023	BUY	$132.51 - $164.9 $521,294 - $648,716	3,934 Added 4.43%	92,816 $14 Million
Q1 2023 May 12, 2023	SELL	$144.61 - $166.54 $12.2 Million - $14.1 Million	-84,689 Reduced 48.79%	88,882 $14.2 Million

Q4 2022 Jan 19, 2023	SELL	$138.31 - $165.87 $1.76 Million - $2.11 Million	-12,693 Reduced 6.81%	173,571 $28.1 Million
Q3 2022 Nov 01, 2022	BUY	$134.21 - $153.93 $80,391 - $92,204	599 Added 0.32%	186,264 $25 Million
Q2 2022 Jul 29, 2022	BUY	$137.62 - $174.96 $8.4 Million - $10.7 Million	61,058 Added 49.0%	185,665 $28.4 Million
Q1 2022 May 11, 2022	BUY	$131.98 - $163.75 $63,482 - $78,763	481 Added 0.39%	124,607 $20.2 Million
Q4 2021 Jan 10, 2022	BUY	$107.43 - $135.93 $929,914 - $1.18 Million	8,656 Added 7.5%	124,126 $16.8 Million
Q3 2021 Oct 21, 2021	BUY	$106.4 - $120.78 $12.3 Million - $13.9 Million	115,470 New	115,470 $12.5 Million
Q3 2021 Oct 13, 2021	SELL	$106.4 - $120.78 $12.1 Million - $13.7 Million	-113,517 Closed	0 $0
Q2 2021 Jul 21, 2021	SELL	$105.21 - $117.21 $9.09 Million - $10.1 Million	-86,390 Reduced 43.22%	113,517 $12.8 Million
Q1 2021 Apr 15, 2021	SELL	$102.3 - $112.62 $351,093 - $386,511	-3,432 Reduced 1.69%	199,907 $21.6 Million
Q4 2020 Jan 14, 2021	SELL	$80.49 - $108.67 $189,875 - $256,352	-2,359 Reduced 1.15%	203,339 $21.8 Million
Q3 2020 Oct 08, 2020	BUY	$85.91 - $100.83 $5.74 Million - $6.74 Million	66,801 Added 48.09%	205,698 $18 Million
Q2 2020 Aug 14, 2020	BUY	$73.37 - $98.18 $1.6 Million - $2.14 Million	21,747 Added 18.56%	138,897 $13.6 Million
Q1 2020 Apr 28, 2020	SELL	$64.5 - $97.79 $4.87 Million - $7.38 Million	-75,438 Reduced 39.17%	117,150 $8.93 Million
Q4 2019 Feb 06, 2020	SELL	$72.13 - $90.25 $55,828 - $69,853	-774 Reduced 0.4%	192,588 $17.1 Million
Q3 2019 Oct 09, 2019	SELL	$62.98 - $75.72 $446,465 - $536,779	-7,089 Reduced 3.54%	193,362 $14.6 Million
Q2 2019 Jul 09, 2019	SELL	$65.7 - $83.98 $385,724 - $493,046	-5,871 Reduced 2.85%	200,451 $14.6 Million
Q1 2019 May 02, 2019	SELL	$77.14 - $90.79 $115,632 - $136,094	-1,499 Reduced 0.72%	206,322 $16.6 Million
Q4 2018 Jan 31, 2019	SELL	$77.85 - $96.01 $462,662 - $570,587	-5,943 Reduced 2.78%	207,821 $19.2 Million
Q3 2018 Nov 08, 2018	SELL	$88.91 - $98.84 $23,650 - $26,291	-266 Reduced 0.12%	213,764 $20.2 Million
Q2 2018 Jul 31, 2018	SELL	$89.78 - $106.23 $565,524 - $669,142	-6,299 Reduced 2.86%	214,030 $19.8 Million
Q1 2018 Apr 16, 2018	SELL	$92.01 - $123.21 $352,674 - $472,263	-3,833 Reduced 1.71%	220,329 $20.9 Million
Q4 2017 Feb 05, 2018	BUY	$89.56 - $98.21 $1.07 Million - $1.18 Million	11,994 Added 5.65%	224,162 $21.7 Million
Q3 2016 Oct 25, 2017	BUY	N/A	212,168	212,168 $18.9 Million

Others Institutions Holding ABBV

# of Institutions

3,653

Shares Held

1.24B

Call Options Held

15.5M

Put Options Held

11.6M

View Full List

About AbbVie Inc.

Ticker ABBV
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 1,768,099,968
Market Cap $290B
Description
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheuma...

More about ABBV

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Crossmark Global Holdings, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Crossmark Global Holdings, Inc. with notifications on news.

Account

Crossmark Global Holdings, Inc. Abb Vie Inc. Transaction History